The 7 most recent market catalysts affecting $TRNS, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Nov 6, 2026
Corporate Catalyst
Neutral
Impact 65
Analysts Update Ratings and Price Targets for Transcat, Inc.
On November 6, 2026, Transcat, Inc. (TRNS) received updated analyst coverage. Craig-Hallum maintained a 'Buy' rating and raised its price target to $119, Oppenheimer upgraded TRNS …
Nov 4, 2026
Corporate Catalyst
Bullish
Impact 65
Oppenheimer Upgrades Transcat to Outperform
Oppenheimer upgraded Transcat (TRNS) to Outperform from Perform, setting a price target of $115. This upgrade is a direct response to Transcat's recent fiscal Q2 2027 earnings, whi…
Nov 3, 2026
Corporate Catalyst
Bullish
Impact 92
Transcat, Inc. Reports Fiscal Second Quarter 2027 Financial Results
Transcat, Inc. announced fiscal Q2 2027 results that significantly exceeded analyst expectations for both adjusted EPS and revenue. This strong performance, particularly the double…
Oct 21, 2026
Corporate Catalyst
Bullish
Impact 65
Northland Securities Upgrades Transcat to Outperform
Northland Securities upgraded Transcat, Inc. (TRNS) from Market Perform to Outperform and established a $95 price target. This analyst upgrade signals increased confidence in Trans…
Oct 21, 2026
Corporate Catalyst
Bearish
Impact 65
Northland Securities Downgrades Transcat to Market Perform
Northland Securities has downgraded Transcat, Inc. from an 'Outperform' to a 'Market Perform' rating, simultaneously setting a price target of $95. This action signals a less optim…
Aug 31, 2026
Corporate Catalyst
Neutral
Impact 65
Transcat Announces Acquisition Of Southeastern Biomedical Associates For $12.8M In Cash, Effective August 31
This acquisition is a positive development for Transcat, as it directly expands their service capabilities in the biomedical sector and strengthens their presence in the Southeaste…
Aug 4, 2026
Corporate Catalyst
Bearish
Impact 92
Transcat Q1 Adj. EPS $0.51 Beats $0.38 Estimate, Sales $92.945M Beat $86.546M Estimate
Transcat (TRNS) announced its Q1 earnings, reporting adjusted EPS of $0.51, which comfortably surpassed the analyst consensus of $0.38. This 34.21% beat on the bottom line, despite…
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.